Follow CLLCANADA on Facebook
~ Follow CLL CANADA ~
For privacy reasons this is a secret Facebook Group. To join, send your email address to the link below, then you will receive an invitation... you must be a Facebook member as well.
Bad to the Bone


Just search

Venclexta, (venetoclax) approved by Health Canada for special use 🇨🇦

This is approved but not funded by the provinces ... please talk to your physician.

Press Release

Oct 4th, 2016

Imbruvica Approved For First line by Health Canada 🇨🇦

IMBRUVICA® significantly improved progression-free, overall survival, and overall response rate versus an established chemotherapy.

Janssen Inc. announced that Health Canada has approved IMBRUVICA® (ibrutinib) an oral, once-daily, single-agent targeted therapy for previously untreated patients with active chronic lymphocytic leukemia (CLL).1 This is the 4th approval for IMBRUVICA®, which now is approved for use in all lines of CLL therapy for patients needing treatment, considerably expanding the number of Canadian patients who may benefit from this chemotherapy-free treatment. Chronic lymphocytic leukemia is one of the most common types of leukemia in adults.

More here: Press Release
July 22, 2016

Current Imbruvica (ibrutinib) Funding in Canada 2016

Which provinces are funding Imbruvica (ibrutinib) in Canada as of January 2016 and what strings are attached... follow the link below. Note: Quebec is not part of this process, but they are funding...

Link Here
Feb 1, 2016

ASH 2015 Abstracts Are Online

This is the Abstracts Search Engine page...


Nov 5, 2015

🇨🇦 New Treatment Perspectives in CLL: Using Disease and Patient Characteristics to Optimize Outcomes

A recent Canadian perspective...

Full Paper New Evidence

Oct 10, 2015

Idelalisib (Zydelig) gets pCODR final recommendation for Canada

Today, the pCODR Expert Review Committee (pERC) issued the final recommendation for idelalisib (Zydelig) for chronic lymphocytic leukemia (CLL). pERC recommends funding idelalisib (Zydelig), conditional on cost-effectiveness being improved to an acceptable level, when used in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). Treatment should continue until unacceptable toxicity or disease progression.

Final Recommendation text

Aug 18, 2015

Gazyva and Chlorambucil

Saskatchewan and Manitoba will be funding, however with some strings attached. Please refer to the document below or consult your doctor.

Other provinces are still pending... Quebec has funded.

Funding Details

July 4, 2015

Wendy's Wish

Wendy's Wish Inc was created to raise awareness of Richter's Transformation, to offer financial and peer support for those effected by Richter's Transformation, and to raise funding for research for Richter's Transformation. It was founded by Wendy Sonlin, a Richter's Transformation patient currently in remission.

Wendy's Wish Website

Wendy's Facebook Page


June 6, 2015

Quebec funds Gazyva

People in Quebec living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the province's prescription drug insurance plan.

Just yesterday, GAZYVA® (obinutuzumab) in combination with chlorambucil chemotherapy was added to Quebec's Hospital Formulary. GAZYVA® was approved by Health Canada on November 25, 2014, in combination with chlorambucil, for the treatment of patients with previously untreated CLL.

Press Release

June 2, 2015

CLL Live 2015 Speaker Videos

YouTube Playlist

May 16, 2015

Blood Cancer Research Fund Conference Speaker Videos

In honor of Miles Pendleton, a CLL patient and advocate, the CLL Research Consortium and the Blood Cancer Research Fund, hosted a patient education and empowerment meeting. The meeting took place at UC San Diego Moores Cancer Center, in La Jolla, California.

Link to Speaker Videos

May 21, 2015

ASCO Abstracts 2015

An annual event... try your search skills....


Also see Dr. Sharman's blog for more targeted information...

ASCO Key Studies

May 13, 2015

New Patient Website

CLL Society Link

April 10, 2015

pCODR Final Recommendation for Ibrutinib

The recommendation is positive if the costs come into line, in provincial negotiations.

It does not mean it is provincially funded anywhere or in any clinic yet...please bear this in mind. This recommendation is not binding on provinces, territories or federally funded plans.

This recommendation starts negotiations between the drug company and provinces for possible provincial funding.

Recommendation Link PDF
March 05, 2015

High Cost of New Medicines

'While Health Canada has approved the use of Imbruvica, which patients could have to take for the rest of their lives, provinces have yet to decide whether they will foot the annual $100,000 per patient bill.'

Canadian cancer specialists meet next week to discuss whether to recommend Imbruvica for provincial coverage.

Dec 12, 2014

pCODR... Ofatumumab/chlorambucil

The pCODR review committee pERC, has issued a draft recommendation that ofatumumab (Arzerra) and chlorambucil NOT be recommended for funding for Canadian CLL patients unsuitable for fludarabine.

There is an appeal process and the final recommendation will be made at a later date.

Decision PDF
Dec 4, 2014

Gazyva ... Health Canada Approved

Roche Canada announced that Health Canada has approved GAZYVA™ (obinutuzumab) to be administered in combination with chlorambucil chemotherapy for the treatment of people with previously untreated CLL.

This is approval for safety and efficacy. It is not available or funded in the clinic yet.

Link Here
Nov 24, 2014

Imbruvica (ibrutinib) gets Health Canada Approval

Janssen Inc. announced today Health Canada has approved IMBRUVICA™ (ibrutinib) for the treatment of the blood cancer chronic lymphocytic leukemia (CLL). It is indicated for the treatment of patients with CLL, including those with 17p deletion, who have received at least one prior therapy, or for the frontline treatment of patients with CLL with 17p deletion.

In CLL, 17p deletion is a genetic mutation that has been associated with poor treatment outcomes.

This DOES NOT MEAN IT IS FUNDED by the provinces yet... it is the first step...

Press Release
Nov 19, 2014

UK ofatumumab/chlorambucil recommended

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending GlaxoSmithKline's Arzerra (ofatumumab) in a form of leukaemia. NICE, which provides health guidance for the NHS in England and Wales, said the drug was a cost-effective option in combination with chlorambucil for untreated chronic lymphocytic leukaemia (CLL) in people who are not eligible for treatment with fludarabine combination therapy and for whom bendamustine is unsuitable.

Ofatumumab’s list price is £182 for a 100 mg vial and £1820 for a 1000 mg vial. Assuming 6 cycles and no drug wastage, the mean cost of a treatment course for ofatumumab at its list price is £11,466 for 6300 mg. The company has agreed a patient access scheme with the Department of Health that makes ofatumumab available with a discount on the list price.
Nice link
Nov 4, 2014


DailyMed provides trustworthy information about marketed drugs in the U.S.

DailyMed is the official provider of FDA label information (package inserts).

This new redesigned Web site provides a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling found in medication package inserts.

To view a specific section in the listing, click or tap on the 'orange plus, beside a topic. The information is also available in PDF format download

This particular page link is for ibrutinib, but you can search any drug in the database of FDA approved treatments...
Link Here
Oct 21, 2014

A Canadian Perspective on the Treatment of Unfit Patients with Chronic Lymphocytic Leukemia

This paper discusses two major issues physicians encounter when treating unfit patients with CLL: (i) What factors enter into the decision that a patient is unfit for FCR therapy? (ii) What are the best treatment options for those patients who are deemed unfit? In addition to reviewing the current evidence, the regional practices of three Canadian experts from Nova Scotia, Quebec, and Alberta will be explored.
Feb 3 , 2014

LLC en français?

This is a link to a French CLL/SLL website... might give it a try.
Dec 10 , 2013

How Cancer Drugs are Approved and Funded in Canada

This tutorial explains the process that decision makers in Canada follow to decide whether to publicly fund new cancer drugs. You’ll learn who is involved in this process, and how health benefits, costs and values play into the decision. At the end of the tutorial, you should be able to answer the following questions:

  • ◊ Which groups make decisions in Canada about publicly funded cancer drugs and how are those decisions made?
  • ◊ How do we know if drugs work and are better than current treatment?
  • ◊ How do costs and benefits fit into the decision making process?
  • ◊ What is a fair decision?
  • ◊ How are decision makers held accountable to the public?
  • ◊ How can you get involved in cancer drug funding decision making panels?

The principles described in this tutorial also apply to decisions about other non- cancer drugs and new health care technologies.
Nov 2, 2013

Flow Cytometry ~ Everything you need to know and more...

Flow Cytometry is a blood test used to diagnose CLL. This video tutorial education program explains how flow cytometry actually works.

This takes about 12 minutes to view... Will NOT work on iPad etc. Needs Flash Player 8

Flow Tutorial LINK HERE

Many other tutorials : LINK HERE

Also see the "How does FISH work?" LINK HERE
Nov 7, 2011

New in CLL
Livingwcll Click Image Above

Now Available

Link Here to CLL TRACKER
The CLL TRACKER has undergone a major revision...

Understand Blood Labs
One of the most complete up-to-date website about blood tests can be found at this link. Well worth bookmarking for future reference.

Lab Tests Online

Guide to Lab Test for CLL

lab_test Click Here

Thanks to Beth for this link

Guide to Bloodwork ~ Complete Blood Count

This is an excellent resource you can save to disc and refer to.
Click Here for PDF

Blood count ranges can be found here:
Note that these ranges do vary from lab to lab and country to country.
Click Here
Meetings and Events

The Leukemia Association of Ottawa

A support group based in Ottawa, Ontario dedicated to helping people with Leukemia and their care-givers, friends, and family.

Meetings are the 4th Tuesday of every month
7:00pm - 9:00pm
Riverside United Church,
3191 Riverside Drive (south of Walkley Rd)

Link to Website

aCGH,CLLTOPICS,Healthunlocked,LLS,LLSC,RICHTER'S,Richter's syndrome,Zydelig (idelalisib),Imbruvica (ibrutinib),IDELA (idelalisib),ABT199, Abt-199,DLBCL,drugs,treatment,LRF,LFC,chronic lymphocytic leukemia,CLL,cll topics,sll,cancer care,chronic,chronic lymphocytic leukaemia,LLSC,lymphocytic,CLL,leukaemia, B-cell, leukemia, NHL, lymphoma, CLL Canada, CLL prognosis, FISH,CLL treatment,cll markers,cll topics,CLL conference,patient education, advocacy, chaya, acor,17p, 11q,13q,trisomy 12,markers,fish,rituxan,FCR,updates,хранічнага лимфолейкоза хронична лимфоцитна левкемия 慢性淋巴细胞白血病 chronické lymfatické leukémie kronisk lymfatisk leukæmi chronische lymfatische leukemie krooniline lümfoidne leukeemia talamak lymphocytic lukemya leucémie lymphoïde chronique chronischer lymphatischer Leukämie לוקמיה לימפוציטית כרונית पुरानी lymphocytic लेकिमिया leoicéime lymphocytic ainsealach 慢性リンパ性白血病 przewlekłej białaczki limfatycznej kronisk lymfatisk leukem χρόνια λεμφοκυτταρική λευχαιμία lėtinė limfocitinė leukemija хронического лимфолейкоза כראָניש לימפאָסיטיק לוקימיאַ lewcemia lymffosytig cronig bệnh bạch cầu lymphocytic mãn tính 만성 림프 구성 백혈병 CLL,chronic lymphocytic leukemia,CLL/SLL,CLL,SLL,Canada,UK,USA,News,chronic lymphocytic leukaemia, SLL small lymphocytic lymphoma, Chaya, topics, hamblin,pci-32765,CAL-101.
Most CLL CANADA readers this week: